Literature DB >> 24704391

A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives.

Monica Lamberti1, Stefania Porto2, Silvia Zappavigna2, Erasmo Addeo2, Monica Marra2, Nadia Miraglia3, Nicola Sannolo3, Daniela Vanacore2, Paola Stiuso2, Michele Caraglia2.   

Abstract

Fluoropyrimidines are key agents for the treatment of gastrointestinal tract adenocarcinomas. The possible cardiotoxic effects in patients and occupationally exposed workers are multifactorial and remain a puzzle to solve for investigators. In the present study, we study what cell death pathways and what doses can determine direct cardiotoxic effects of 5-fluorouracil (5-FU) and doxorubicin (DOXO) on rat cardiocytes (H9c2) and a human colon adenocarcinoma (HT-29) cell line, already reported to be sensitive to 5-FU. We have found that 5-FU induced 50% growth inhibition (IC:50) at 72 h with concentrations of 400 μM and 4 μM on H9c2 and HT-29, respectively. Moreover, we have found that the addition of Levofolinic Acid (LF) to 5-FU potentiated the growth inhibition induced by 5-FU. The growth inhibition induced by 5-FU alone or in combination with LF in cardiocytes was paralleled by an increase of thiobarbituric acid-reactive species (Tbars) and end products of nitric oxide (NO) suggesting the increase of the oxidative stress status in cardiocytes. Interestingly, these effects were strongly potentiated by the addition of LF, a biochemical modulator of 5-FU activity. Our data suggest that agents such as 5-FU different from anthracyclines, conventionally related to the induction of cardiotoxic effects, can also induce cardiocyte damage paralleled by oxidative stress. The strategies based upon the use of scavengers could be used in order to prevent this effect.
Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  5-Fluorouracil; Cardiotoxicity; Occupational health; Rat cardiocytes model

Mesh:

Substances:

Year:  2014        PMID: 24704391     DOI: 10.1016/j.toxlet.2014.03.018

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  9 in total

1.  Rapidly developing heart failure from capecitabine cardiotoxicity: a case study.

Authors:  Paurush Ambesh; Kaveh Zivari; Chukwudi Obiagwu; Vijay Shetty; Stephan Kamholz; Gerald Hollander; Jacob Shani
Journal:  Br J Clin Pharmacol       Date:  2018-02-09       Impact factor: 4.335

Review 2.  From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors:  Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal:  Antioxid Redox Signal       Date:  2017-05-15       Impact factor: 8.401

Review 3.  Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.

Authors:  Michael E Layoun; Chanaka D Wickramasinghe; Maria V Peralta; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

4.  Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes.

Authors:  Chiara Focaccetti; Antonino Bruno; Elena Magnani; Desirée Bartolini; Elisa Principi; Katiuscia Dallaglio; Eraldo O Bucci; Giovanna Finzi; Fausto Sessa; Douglas M Noonan; Adriana Albini
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

5.  Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: clinical and occupational implications.

Authors:  Monica Lamberti; Stefania Porto; Silvia Zappavigna; Paola Stiuso; Virginia Tirino; Vincenzo Desiderio; Luigi Mele; Michele Caraglia
Journal:  Int J Oncol       Date:  2015-02-24       Impact factor: 5.650

Review 6.  Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.

Authors:  Gilda Varricchi; Pietro Ameri; Christian Cadeddu; Alessandra Ghigo; Rosalinda Madonna; Giancarlo Marone; Valentina Mercurio; Ines Monte; Giuseppina Novo; Paolo Parrella; Flora Pirozzi; Antonio Pecoraro; Paolo Spallarossa; Concetta Zito; Giuseppe Mercuro; Pasquale Pagliaro; Carlo G Tocchetti
Journal:  Front Physiol       Date:  2018-03-07       Impact factor: 4.566

Review 7.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

8.  Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?

Authors:  Caterina Fontanella; Marianna Aita; Marika Cinausero; Giuseppe Aprile; Maria Grazia Baldin; Veronica Dusi; Chiara Lestuzzi; Gianpiero Fasola; Fabio Puglisi
Journal:  Onco Targets Ther       Date:  2014-09-29       Impact factor: 4.147

Review 9.  Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?

Authors:  Marc D Piroth; David Krug; Felix Sedlmayer; Marciana-Nona Duma; René Baumann; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Rainer Souchon; Vratislav Strnad; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2020-07-31       Impact factor: 3.621

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.